ClinicalTrials.gg
RecruitingNCT04775108Updated Aug 7, 2023

First-In-Human Clinical Study for Treatment of Severe Mitral Valve INsufficiency With Epygon™ TRanscatheter Mitral VAlve System

An interventional study of Epygon™ Transcatheter Mitral Valve System in Mitral Valve Regurgitation, sponsored by Epygon. Recruiting at 10 sites in 4 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2023-08-07.

Sponsored by Epygon · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Mitral Valve Insufficiency with a site in Spain — 11 open to participants now, 15 under way, none of them phase 3. Mitral Valve Insufficiency · Spain.

Planned enrollment
8th of 12
40 · median 204
Started
2021
with 3 others
No phase
11 of 20
7 open now
Primary completion
2024-10
later than 2 of 14 live
Registered
10th of 20
by date
Lead sponsor
1 of 20
Epygon

Among the 20 studies in Mitral Valve Insufficiency with a site in Spain, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2021, is one of 11 with no phase, reaches primary completion later than 2 of the 14 other live ones, and was the 10th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

11 of the 20 studies in Mitral Valve Insufficiency with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Mitral Valve Insufficiency with a site in Spain, or all of them as a file.
02

Study summary

The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedure by means of a dedicated implant device.

The EPYGON VALVE is a bio prosthesis, composed by a functional assembly of bovine pericardium on a NiTinol stent.

The purpose of this trial is to assess the safety and feasibility of the Epygon™ Transcatheter mitral valve and the transapical delivery system, in adult patients with severe, symptomatic mitral regurgitation.

03

Conditions studied

  • Mitral Valve Regurgitation

Keywords

  • Mitral regurgitation
  • Mitral valve replacement
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients of age ≥ 60 years.
  2. Patients with primary or secondary severe symptomatic mitral valve regurgitation.
  3. Patients with severe, symptomatic mitral regurgitation and who have been evaluated by a multidisciplinary Heart Team and deemed to be ineligible for conventional valve surgery and not eligible for transcatheter repair.
  4. Patients with a ≥ 30%.
  5. Patients in functional classes III to IV.
  6. Patients who have clearly accepted participation in this clinical study and who have signed the .
  7. Patients who are willing to accept and undergo all protocol related requirements.
  8. Patients not planning to transfer abroad.

Exclusion criteria

Exclusion Criteria:

  • Clinical exclusion criteria (preoperative screening)
  1. Patients involved in other clinical assessments for drugs or devices that could interfere or alter the study endpoints.
  2. Patients with clinical/anatomical conditions unsuitable for a transapical surgical approach.
  3. Patients who have previously undergone implantation of a transcatheter aortic valve prosthesis.
  4. Patients with previous implantation of a mitral heart valve prosthesis.
  5. Patients with previous implantation of a mitral annuloplasty ring.
  6. Patients needing emergency or life-saving interventions.
  7. Patients with a heavily calcified mitral annulus and/or anterior mitral leaflet.
  8. Patients with active infection or endocarditis (suspect endocarditis included).
  9. Patients with echocardiographic evidence of intracardiac mass or thrombus.
  10. Patients which suffered an acute myocardial infarction within 30 days of the intended treatment (defined as: Q wave MI, or non-Q wave MI with elevation of CK-MB ≥ 3 times normal in the absence of pathological Q waves), if no assay for CK-MB was performed, elevation of CK level to >2 times normal without new Q waves, or elevated Troponin level is also considered a non-Q wave MI).
  11. Patients with an active peptic ulcer or upper GI bleeding within the prior 30 days.
  12. Patients with a documented allergy towards contrast media, and to any compound of the investigated medical device.
  13. Patients that have neurological disease severely affecting ambulation or day to day functioning.
  14. Patients with any stroke within the prior 30 days.
  15. Patients with senile dementia, according to the advice from a specialized neurologist.
  16. Patients in whom transesophageal echocardiography (TEE) is since TEE is used for both preoperative screening and guidance during implant procedure.
  17. Patients who is unwilling or deemed by the Investigator to be unwilling to comply with the requirements of the protocol, or subject with a history of non-compliance.
  18. Patients unable to understand and sign the Form in absence of legal representative.
  19. Patients with a lack of capacity to consent.
  20. Patients unable to read and write.

    • Echographic exclusion criteria (preoperative screening)
  21. Patients with left ventricular apex aneurysm;
  22. Patients with aorto-mitral angle \<120°;
  23. Patients with a systolic/diastolic mitral valve area assessed as not compatible with the sizing policy matrix defined by the Sponsor.

    • Computerized Tomographic (CT) exclusion criteria (preoperative screening)
  24. Patients with ventricular morphology (position of papillary muscles, ventricular wall hypertrophy) unsuitable with the study valve design;
  25. Patients with aorto-mitral angle \<120°;
  26. Patients with a systolic/diastolic mitral valve area assessed as not compatible with the sizing policy matrix defined by the Sponsor.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Implanted patients

    Implantation of Epygon mitral valve prosthesis

    Device: Epygon™ Transcatheter Mitral Valve System

Interventions

  • DeviceEpygon™ Transcatheter Mitral Valve System

    The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedure by means of a dedicated implant device. The EPYGON VALVE is a bio prosthesis, composed by a functional assembly of bovine pericardium on a NiTinol stent.

06

What researchers measure

Primary outcomes

  1. Device Safety

    defined as the absence of major device or procedure related serious adverse events evaluated on the following clinical events: 1. death 2. major cardiac structural complications (as per MVARC definitions) 3. life-threatening bleeding (MVARC scale) 4. any prosthesis-related dysfunction, migration, thrombosis, or other complication, that require surgery or repeated intervention. 5. myocardial infarction or coronary ischemia requiring PCI or CABG 6. severe hypotension, heart failure or respiratory failure requiring intravenous vasopressors or invasive or mechanical heart failure treatments such as ultrafiltration or hemodynamic assist devices, including intra-aortic balloon pumps or left ventricular or biventricular assist devices, or prolonged intubation for ≥ 48H 7. major vascular complications 8. stroke 9. stage 2 or 3 acute kidney injury (includes new dialysis)

    Time frame: [Timeframe: at 30 days]

  2. Device Success

    1. Technical Success (as per MVARC definition) defined as alive patient at exit from procedure room, with all of the following: 1. Successful access, delivery and retrieval of the Epygon delivery system 2. Successful deployment and positioning of the Epygon Transcatheter mitral valve 3. Freedom from additional emergency surgery or re-intervention related to the device or access procedure. 2. Continued intended safety and performance of the device, including: 1. No evidence of structural or functional failure (as per MVARC definition) 2. No specific device-related technical failure issues and complications (as per MVARC definition) 3. Reduction of mitral regurgitation (MR) to either optimal (0+ to trace) or acceptable (reduced by at least 1 grade from baseline with no more than 2+ MR) without significant mitral stenosis (post-procedure EOA ≥ 1.5 cm2 with a transmitral gradient \< 5mmHg) and with no greater than mild (1+) paravalvular MR (and without associated hemolysis)

    Time frame: [Timeframe: at 30 days]

Secondary outcomes

  1. Device Safety

    defined as absence of major device or procedure related serious adverse events evaluated on the following clinical events: 1. death 2. major cardiac structural complications 3. life-threatening bleeding (MVARC scale) 4. any prosthesis-related dysfunction, migration, thrombosis, or other complication, that require surgery or repeated intervention. 5. myocardial infarction or coronary ischemia requiring PCI or CABG 6. severe hypotension, heart failure or respiratory failure requiring intravenous vasopressors or invasive or mechanical heart failure treatments such as ultrafiltration or hemodynamic assist devices, including intra-aortic balloon pumps or left ventricular or biventricular assist devices, or prolonged intubation for ≥ 48H 7. major access complications 8. stroke 9. stage 2 or 3 acute kidney injury (includes new dialysis)

    Time frame: [Time frame: 3, 6, 12 months and yearly up to 5 years from implantation]

  2. Patient success (as per MVARC definition)

    All of the following must be present: 1. Device success (either optimal or acceptable) 2. Patient returned to the pre-procedural setting 3. No rehospitalizations or reinterventions for the underlying condition (e.g., mitral regurgitation, heart failure) 4. Improvement from baseline in symptoms (e.g., NYHA improvement by ≥ 1 functional class) 5. Improvement from baseline in functional status (e.g., 6-min walk test improvement by ≥ 50 m) 6. Improvement from baseline in quality-of-life (e.g., Kansas City Cardiomyopathy Questionnaire improvement by ≥ 10)

    Time frame: [Time frame: 12 months from implantation]

  3. Evaluation of clinical status on the basis of the NYHA functional classification

    Time frame: [Time frame Preoperative, 30 days, 3, 6, 12 months and yearly up to 5 years from implantation]

  4. Six-minute walk test

    Time frame: [Time frame: Preoperative, 30 days, 3, 6, 12 months and yearly up to 5 years from implantation]

  5. Quality of Life score (Kansas City Cardiomyopathy Questionnaire)

    The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

    Time frame: [Time frame: Preoperative, 3, 6, 12 months and yearly up to 5 years from implantation]

  6. Hemodynamic performance assessed by echocardiography

    1. Prosthetic mean atrio-ventricular ΔP \< 5 mm Hg 2. Prosthetic Effective Orifice Area (EOA) ≥ 1.5 cm2 3. Mitral valve regurgitation reduction (vs. preoperative) of at least 1 grade and not more than moderate (2+) 4. Prosthetic paravalvular valve leakage (PVL) not more than mild (1+) without hemolysis

    Time frame: [Time frame: Preoperative on native mitral valve, Postoperative, 30 days, 3, 6, 12 months and yearly up to 5 years from implantation]

  7. Technical Success (as per MVARC definition)

    defined as alive patient at exit from procedure room, with all of the following: 1. Successful access, delivery and retrieval of the Epygon delivery system 2. Successful deployment and positioning of the Epygon Transcatheter mitral valve 3. Freedom from additional emergency surgery or re-intervention related to the device or access procedure.

    Time frame: [Time Frame: immediately after procedure]

  8. Device Success

    1. Technical Success (as per MVARC definition) defined as alive patient at exit from procedure room, with all of the following: 1. Successful access, delivery and retrieval of the Epygon delivery system 2. Successful deployment and positioning of the Epygon bioprosthesis 3. Freedom from additional emergency surgery or re-intervention related to the device or access procedure. 2. Continued intended safety and performance of the device, including: 1. No evidence of structural or functional failure (as per MVARC definition) 2. No specific device-related technical failure issues and complications (as per MVARC definition) 3. Reduction of mitral regurgitation (MR) to either optimal (0+ to trace) or acceptable (reduced by at least 1 grade from baseline with no more than 2+ MR) without significant mitral stenosis (post-procedure EOA ≥ 1.5 cm2 with a transmitral gradient \< 5mmHg) and with no greater than mild (1+) paravalvular MR (and without associated hemolysis)

    Time frame: [Time frame: 3, 6, 12 months and yearly up to 5 years from implantation]

  9. Procedural Success

    All of the following must be present: 1. Device success (either optimal or acceptable), And 2. Absence of major device or procedure related serious adverse events, including: 1. death 2. major cardiac structural complications (as per MVARC definitions) 3. life-threatening bleeding (MVARC scale) 4. any prosthesis-related dysfunction, migration, thrombosis, or other complication, that require surgery or repeated intervention. 5. myocardial infarction or coronary ischemia requiring PCI or CABG 6. severe hypotension, heart failure or respiratory failure requiring intravenous vasopressors or invasive or mechanical heart failure treatments such as ultrafiltration or hemodynamic assist devices, including intra-aortic balloon pumps or left ventricular or biventricular assist devices, or prolonged intubation for ≥ 48H 7. major vascular complications 8. stroke 9. stage 2 or 3 acute kidney injury (includes new dialysis).

    Time frame: [Time frame: 30 days]

  10. Incidence of adverse events

    Time frame: [Time frame: 30 days, 3, 6, 12 months and yearly up to 5 years from implantation]

  11. Incidence of serious adverse events

    Time frame: [Time frame: 30 days, 3, 6, 12 months and yearly up to 5 years from implantation]

  12. Incidence of adverse events related to device

    Time frame: [Time frame: 30 days, 3, 6, 12 months and yearly up to 5 years from implantation]

  13. Incidence of adverse events related to procedure

    Time frame: [Time frame: 30 days, 3, 6, 12 months and yearly up to 5 years from implantation]

  14. Absence of all-cause mortality

    Time frame: [Time frame: 30 days, 3, 6, 12 months and yearly up to 5 years from implantation]

07

Study locations

8 of 10 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Oct 2024, 44 months after the start.

Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 44 months is below that.

Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2021
First posted
Mar 1, 2021
StartActual
Feb 1, 2021
Primary completionEst.
Oct 31, 2024
CompletionEst.
Dec 31, 2029
Last update
Aug 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04775108
Lead sponsor
Epygon
Responsible party
Sponsor
First posted
Mar 1, 2021
Start date
Feb 1, 2021
Primary completion
Oct 31, 2024 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Aug 7, 2023

Study contacts

Christophe Giot
Contact
christophe.giot@affluentmedical.com
+33 4 42 95 12 20

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion